Small Cell Lung Cancer – Pharmacosmos P-Trilaciclib-LS-SCLC-01

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:

Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?

Participants will be randomised to receive either trilaciclib or placebo.

Inclusion Criteria:

• Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
• Complete recovery from prior anti-tumor surgical procedures
• Measurable and evaluable disease through tumor assessment
• Willingness to participate and sign informed consent form

Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.